Intro

This chapter explores the MYPP trial, assessing the impact of daily myo-inositol supplementation in pregnant individuals with polycystic ovary syndrome (PCOS). It reveals that despite common pregnancy complications linked to PCOS, the supplement did not significantly lower the risks of gestational diabetes, preeclampsia, or preterm birth compared to a placebo.